Q2 费用率18.9%，同比提升8 个pct，预计一是产线建设导致费用化支出增加；二是新品推广前期人员 增加较多。最终Q2 归属净利润小幅盈利，净利率同比下滑8.8pct。 收并购推进，向上游扩张。公司与上海妙翔等签订股权转让协议，公司拟合计受让标的公司苏州创扬新 材料科技股份有限公司3405 万股股份，转让价款合计为8400 万元，转让完成后公司持股标的公司30% 股份，标的公司主营药用塑料组合盖等，并承诺2025-2027年归属净利润不低于2500 万元、3500 万元、 4500 万元。 从管制到模制，从制瓶到拉管。公司最早从事低硼硅药用玻璃销售，后逐步切入中硼硅领域，并在管制 瓶领域处领先地位。展望未来，公司优势产品中硼硅管制瓶将继续扩张。此外产品的横纵向扩张也将加 速，一方面中硼硅模制瓶有望放量，另一方面开始切入管制瓶上游拉管生产。公司2024 年4 月底中硼硅 模制瓶的注射剂瓶通过转A、10 月输液瓶通过转A，后续随着其他客户的备案完成公司模制瓶有望进入 放量周期。 事件描述 公司上半年实现收入5.0 亿，同比下滑11.1%；归属净利润0.4 亿 ，同比下滑20.1%。折合Q2 收入2.23 亿， ...

Group 1: Company Performance - In 2024, the company achieved a historical high in revenue of 1.081 billion CNY, representing a year-on-year growth of 14.09% [3] - The net profit attributable to shareholders remained stable at 66.07 million CNY, consistent with the previous year [3] - Total assets reached 2.356 billion CNY, reflecting a year-on-year increase of 9.54% [3] Group 2: Business Strategy and Outlook - The company focuses on the pharmaceutical packaging and heat-resistant glass sectors, aiming to strengthen its position as a market leader [2] - There is an ongoing expansion of production capacity for borosilicate products, with expectations for continued growth in the future [3] - The company plans to enhance its market share in the pharmaceutical packaging sector by leveraging its technical reserves and customer resources [3] Group 3: Share Buyback and Financial Management - As of May 13, the company has repurchased 2,325,800 shares, accounting for 1.00% of the total share capital [4] - The buyback plan will continue based on market conditions [4] Group 4: International Expansion - The company has prioritized global development, with significant progress in Latin America and the Middle East [5] - In January 2024, the company signed an investment framework agreement to acquire 51% of The European Ampoules Company in Egypt [5] - A cooperation investment agreement was signed with SANTISA ABORATORIO FARMACEUTICO S/A in March 2025 to further expand market reach [6]

Investment Rating - The investment rating for the company is "Buy" and is maintained [5]. Core Views - The company achieved a revenue of 1.081 billion in 2024, representing a year-on-year growth of 14.09%, with a net profit attributable to shareholders of 66 million, a slight increase of 0.23% [2][4]. - In Q1 2025, the company reported a revenue of 276 million, a year-on-year increase of 3.4%, and a net profit of 41 million, showing a significant growth of 63.4% [2][4]. - The company is expected to benefit from the rapid expansion of its borosilicate glass products and a recovery in daily-use glass, with projected net profits of 160 million and 220 million for 2025 and 2026, respectively, corresponding to PE ratios of 26 and 19 [7]. Financial Performance - In 2024, the company’s revenue was 1.081 billion, with a gross profit of 205 million, resulting in a gross margin of 19%, an increase of 1.6 percentage points year-on-year [7]. - The revenue from pharmaceutical glass reached 470 million, growing by 15.02%, while the revenue from heat-resistant glass was 588 million, up by 13.39% [7]. - The gross margin for Q1 2025 improved significantly to 26.5%, a year-on-year increase of 5.7 percentage points, marking the best Q1 performance since 2021 [7]. Market Outlook - The company is positioned to expand its market share in the borosilicate glass sector, particularly in the injection bottle segment, which is expected to see increased production volume [7]. - The pharmaceutical glass market in China is projected to grow from 350 billion in 2023 to 442 billion by 2026, with a CAGR of 8.51% from 2023 to 2026 [7]. - The company’s strategic focus on both horizontal and vertical expansion in product offerings is anticipated to enhance its competitive edge in the market [7].